Draft:InBody
 | A major contributor to this article appears to have a close connection with its subject. (May 2026) |
 | Review waiting, please be patient.
This may take 3 months or more, since drafts are reviewed in no specific order. There are 4,454 pending submissions waiting for review.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Reviewer tools
|
Submission declined on 26 May 2026 by Grapesurgeon (talk).
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
This draft has been resubmitted and is currently awaiting re-review. |  |
Submission declined on 10 May 2026 by Devonian Wombat (talk). This draft reads like an advertisement. Wikipedia is an encyclopedia, not a platform for promotion or marketing. Drafts that are exclusively promotional may be deleted without notice.
Wikipedia articles must be written neutrally in a formal, impersonal, and dispassionate way. They should not read like a blog post, advertisement, or fan page. Rewrite the draft to remove:
Instead, only summarize in your own words a range of independent, reliable, published sources that discuss the subject. If you have a conflict of interest (e.g. you are the subject, an employee, or a relative) or are being paid to edit, you must disclose this to comply with Wikipedia's Terms of Use.This draft's references do not show that the subject meets Wikipedia's criteria for inclusion for organizations and companies. The draft requires multiple published secondary sources that:
Declined by Devonian Wombat 27 days ago.
| |
Submission declined on 26 March 2026 by Grapesurgeon (talk). This draft's references do not show that the subject meets Wikipedia's criteria for inclusion for organizations and companies. The draft requires multiple published secondary sources that:
Declined by Grapesurgeon 2 months ago.
| |
Submission declined on 13 March 2026 by Pythoncoder (talk). This draft appears to contain text generated by a large language model (such as ChatGPT). You cannot use LLMs to generate article content.
Declined by Pythoncoder 2 months ago.LLM-generated pages with certain obvious signs of being machine generated may be deleted without notice. These tools are prone to specific issues that violate our policies:
Instead, only summarize in your own words a range of independent, reliable, published sources that discuss the subject. See the advice page on large language models for more information. | |
Comment: Still lacking independent coverage. This company is very likely notable, but you need to prove it better with sourcing. grapesurgeon (talk) 17:49, 26 May 2026 (UTC)
- Comment: The sources are largely like press releases; need more independent coverage. Also there's a good chunk of unsourced text in article. grapesurgeon (talk) 23:30, 26 March 2026 (UTC)
Native name | 인바디 |
|---|---|
Company type | Public |
| Industry | Medical devices |
| Founded | 1996 |
| Founder | Ki-Chul Cha |
| Headquarters | Seoul, South Korea |
Key people | Ki-Chul Cha (Founder and CEO) |
| Products | Body composition analyzers, body water analyzers, blood pressure monitors |
| Website | www |
InBody Co., Ltd. is a South Korean medical device manufacturer that develops body composition analyzers based on bioelectrical impedance analysis (BIA) technology. Founded in 1996 and headquartered in Seoul, South Korea, the company produces body composition analyzers used in healthcare, research, sports science, and fitness industries.
InBody devices measure body composition indicators such as skeletal muscle mass, body fat mass, phase angle and total body water distribution.
History
The company was founded in 1996 by Ki-Chul Cha[1][2], a biomedical engineer who began developing the concept during his PhD studies at the University of Utah in 1992. Dr. Cha recognized that existing BIA devices were limited, and he developed a device using a different methodology, which became the first InBody product (InBody 2.0). The company was initially established under the name Biospace Co., Ltd. and later changed its name to InBody.[citation needed]
In 1999, the company signed a BIA technology transfer agreement with Yamato Scale in Japan.[citation needed]
In 2000, the company was listed on the KOSDAQ market and established its first overseas subsidiary in the US.[citation needed]
According to The Korea Herald, the company opened a plant specializing in body composition analyzers in Cheonan, South Chungcheong Province, in 2004.[3]
In 2013, the company's InBody 770, InBody 570, and InBody S10 devices received U.S. Food and Drug Administration (FDA) 510(k) clearance.[4]
Its products are exported to more than 110 countries.[5] The company’s headquarters is in Seoul, and it has subsidiaries in United States, China, Japan, Mexico, India, Netherlands, Malaysia, Singapore, United Kingdom, Vietnam, Australia, Turkiye. Its body composition analyzers are used in medical, research, sports science, and fitness settings.[citation needed]
In 2023, the company signed a contract to supply body composition analyzers to the United States Marine Corps.[6]
In October 2025, Naver announced a partnership with InBody and acquired an 8.5 percent stake in the company.[7]
Technology
Since its founding, InBody has specialized in body composition analyzers using bioelectrical impedance analysis (BIA) technology. The company's devices employ direct segmental multi-frequency bioelectrical impedance analysis (DSM-BIA) and simultaneous multi-frequency bioelectrical impedance analysis (SMF-BIA) to estimate indicator's fat mass, skeletal muscle mass, lean body mass, and total body water. Its products are used in medical, research, sports science, and fitness settings.[citation needed]
Simultaneous multi-frequency BIA measurement was introduced in the InBody770.[8]
A 3 MHz frequency measurement system was later applied to the InBody970 and BWA 2.0 models.[2]
Products
The company's product portfolio includes:[9]
- Body composition analyzers
- Medical Body water analyzers
- Automatic blood pressure monitors
- Stadiometers
- Consumer health monitoring devices: Watch, home-use BIA devices (InBodyDial, H20, H30, H40)
- InBody measurement data management software - LookinBody120, LookinBody Web
Corporate Structure
InBody Co., Ltd. has the following subsidiaries:[10]
- InBody USA, Cerritos, CA, United States
- InBody Japan, Tokyo, Japan
- InBody China, Shanghai, China
- InBody China Medical Technology, Shanghai, China
- InBody Europe, Amsterdam, Netherlands
- InBody Türkiye, Istanbul, Türkiye
- InBody UK, Uxbridge, United Kingdom
- InBody India, Mumbai, India
- InBody Asia, Kuala Lumpur, Malaysia
- InBody Asia Pte., Singapore
- InBody Mexico, Mexico City, Mexico
- InBody Oceania, Queensland, Australia
- InBody New York, Audubon, PA, United States
- InBody Vietnam, Ho Chi Minh City, Vietnam
References
- ^ "[Who Is ?] 차기철 인바디 각자대표이사 회장". [Who Is ?] 차기철 인바디 각자대표이사 회장 (in Korean). 2024-11-04. Retrieved 2026-05-28.
- ^ a b "차기철 인바디 회장". Forbes Korea. 26 June 2025. Retrieved 31 March 2026.
- ^ "InBody to benefit from aging, fare well globally". The Korea Herald. 2016-09-26. Retrieved 2026-05-28.
- ^ "510(k) Premarket Notification". www.accessdata.fda.gov. Retrieved 2026-05-28.
- ^ "[K-Healthcare Goes Global] InBody's global leaders propel body composition analyzer's worldwide growth". Korea Biomedical Review. 19 December 2024. Retrieved 28 May 2026.
- ^ "US Marine Corps to Receive Body Analysis Technology". The Defense Post. 27 January 2023. Retrieved 22 May 2026.
- ^ "Naver partners with InBody to enter global digital health care market". Yonhap News Agency. 31 October 2025. Retrieved 16 March 2026.
- ^ US patent 8271079, "Simultaneous multi-frequency impedance measurement", issued 2012-09-18, assigned to Biospace Co., Ltd.
- ^ "InBody to release big data-based health management solutions". The Korea Economic Daily. 2023-03-15. Retrieved 2026-03-24.
- ^ "InBody HQ". www.inbody.co.kr (in Korean). Retrieved 2026-05-28.
External links
Content Disclaimer
Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.
- The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
- There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
- It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
- Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
- Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.
- provide significant coverage: discuss the subject in detail, excluding routine coverage like product launches, staff appointments, or financial reports and listings in databases or listicles;
- are reliable: from reputable outlets with editorial oversight;
- are independent: not connected to the subject, such as press releases, the subject's own website, or sponsored content.
Please add references that meet all three of these criteria. If none exist, the subject is not yet suitable for Wikipedia.